Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-30T20:27:48.976Z Has data issue: false hasContentIssue false
  • English
  • Français

Olanzapine in the long-term treatment of schizophrenia

Published online by Cambridge University Press:  06 August 2018

John Kane
John Kane*
Affiliation:
Department of Psychiatry, Long Island Jewish Medical Center, Albert Einstein College of Medicine, Glen Oaks, NY 11004, USA
Get access Rights & Permissions [Opens in a new window]

Abstract

The primary aim of the long-term treatment of patients with schizophrenia is to prevent relapse, which is costly both in psychological and economic terms. Although with conventional antipsychotic drugs relapse may occur despite compliance with maintenance regimens, the rate of relapse is reduced in compliant patients. However, this benefit is achieved at the cost of side-effects and the risk of developing tardive dyskinesia, even among patients who have taken these drugs for only a year or two. To provide the therapeutic benefits of maintenance medication without its drawbacks, intermittent dosing and long-term therapy with reduced doses of conventional medications have been explored. The atypical antipsychotic agent, olanzapine, has been shown to be effective maintenance medication and has an improved safety profile.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 174 , Issue S37: Focus on schizophrenia , February 1999 , pp. 26 - 29
Copyright
Copyright © The Royal College of Psychiatrists, 1999 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Chakos, M. H., Alvir, J. M. J., Woerner, M. G., et al (1996) Incidence and correlates of tardive dyskinesia in first-episode schizophrenia. Archives of General Psychiatry, 53, 313–319.Google Scholar
Cheung, H. K. (1981) Schizophrenics fully remitted on neuroleptics for 3–5 years: to stop or continue drugs? British Journal of Psychiatry, 138, 490–494.CrossRefGoogle ScholarPubMed
Chien, C. P. (1975) Drugs and rehabilitation in schizophrenia. In Drugs in Combination with Other Therapies (ed. Greenblatt, M.), pp. 13–34. New York: Grune & Stratton.Google Scholar
Crawford, R. & Forrest, A. (1974) Control trial of depot fluphenazine in outpatient schizophrenics. British Journal of Psychiatry, 124, 385–391.Google Scholar
Crow, T. J., McMillan, J. F., Johnson, A. L., et al (1986) A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry, 148, 120–127.CrossRefGoogle ScholarPubMed
Dencker, S. J., Lapp, M. & Malm, U. (1980) Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study. Acta Psychiatrica Scandinavica, 279 (suppl.), 64–76.Google Scholar
Falloon, I. R. H., Watts, D. C. & Shepherd, M. (1978) A comparative controlled trial of pimozide and fluphenazine decanoate in continuation therapy of schizophrenia. Psychological Medicine, 8, 59–70.Google Scholar
Gilbert, P. L., Harris, M. J., McAdams, L. A., et al (1995) Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Archives of General Psychiatry, 52, 173–188.Google Scholar
Hogarty, G. E., Goldberg, S. C. & the Collaborative Study Group (1974) Drug and sociotherapy in the aftercare of schizophrenic patients: one year relapse rates. Archives of General Psychiatry, 28, 54–64.Google Scholar
Hogarty, G. E., Ulrich, R. F., Mussare, F., et al (1976) Drug discontinuation among long term successfully maintained schizophrenic outpatients. Diseases of the Nervous System, 37, 494–500.Google Scholar
Johnson, D. A. W. (1976) The duration of maintenance therapy and chronic schizophrenia. Acta Psychiatrica Scandinavica, 53, 298–301.Google Scholar
Johnson, D. A. W. (1979) Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia. British Journal of Psychiatry, 135, 524–530.Google Scholar
Kane, J. M. (1983) Problems of compliance in the outpatient treatment of schizophrenia. Journal of Clinical Psychiatry, 44, 3–6.Google Scholar
Kane, J. M. (1995) Tardive dyskinesia: epidemiological and clinical presentation. In Psychopharmacology: The Fourth Generation of Progress (eds F. E. Bloom & D. J. Kupfer), pp. 1485–1495. New York: Raven Press.Google Scholar
Kane, J. M. (1996) Schizophrenia. New England Journal of Medicine, 334, 34–41.CrossRefGoogle ScholarPubMed
Kane, J. M., Quitkin, F., Rifkin, A., et al (1982) Fluphenazine versus placebo in patients with remitted acute first-episode schizophrenia. Archives of General Psychiatry, 39, 70–73.Google Scholar
Kane, J. M., Woerner, M. & Sarantokos, S. (1986) Depot neuroleptics: a comparative review of standard, intermediate and low-dose regimens. Journal of Clinical Psychiatry, 47, 30–33.Google Scholar
Kreisman, D., Blumenthal, R., Borenstein, W., et al (1988) Family attitudes and patient social adjustment in a longitudinal study of outpatient schizophrenics receiving low-dose neuroleptics: the family's view. Psychiatry, 51, 3–13.Google Scholar
Leff, J. P. & Wing, J. K. (1971) Trial of maintenance therapy in schizophrenia. British Medical Journal, iii, 559–604.Google Scholar
Loebel, A. D., Lieberman, J. A., Alvir, J. M. J., et al (1992) Duration of psychosis and outcome in first episode schizophrenia. American Journal of Psychiatry, 149, 1183–1188.Google Scholar
McCreadie, R. G., Dingwall, J. M., Wiles, D. H., et al (1980) Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry, 137, 510–517.Google Scholar
McCreadie, R. G., Wiles, D., Grant, S. M., et al (1988) The Scottish first episode schizophrenia study. V. One year follow-up. British Journal of Psychiatry, 152, 470–476.Google Scholar
Moscarelli, M., Capri, S. & Neri, L. (1991) Cost evaluation of chronic schizophrenic patients during the first three years after the first contact. Schizophrenia Bulletin, 17, 421–426.Google Scholar
Muller, P. (1983) Was sollen wir Schizophrenen raten: Medikamentose Langzeitprophylaxe oder Intervallbehandlung? Nervenarzt, 54, 477–485.Google Scholar
Overall, J. E. & Gorham, D. R. (1962) The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799–812.Google Scholar
Prudo, R. & Blum, M. (1987) Five year outcome and prognosis in schizophrenia. British Journal of Psychiatry, 150, 345–354.Google Scholar
Rabiner, C. J., Wagner, J. T. & Kane, J. M. (1986) Outcome study of first episode psychosis: relapse rates after one year. American Journal of Psychiatry, 143, 1155–1158.Google Scholar
Rajkumar, S. & Thara, R. (1989) Factors affecting relapse in schizophrenia. Schizophrenia Research, 2, 403–409.Google Scholar
Tollefson, G. D., Beasley, C. M. Jr & Tamura, R. N. (1997) Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry, 154, 1248–1254.Google Scholar
Tran, P. V., Dellva, M. A., Tollefson, G. D., et al (1998) Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. British Journal of Psychiatry, 172, 499–505.Google Scholar
Wistedt, B. (1981) A depot neuroleptic withdrawal study: a controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiatrica Scandinavica, 64, 65–84.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.